Loading data for XFOR — first visit, this takes a few seconds.
X4 Pharmaceuticals Inc. (XFOR)
NasdaqCM: XFOR
· Real-Time Price · USD
4.16
-0.05 (-1.19%)
At close: Aug 19, 2026, 3:59 PM
4.16
+0.00%
After-hours: 4:10 PM
X4 Pharmaceuticals Inc. (XFOR) Stock Price, Analysis & Data
-1.19% (1D)
| Bid | 4.18 |
| Market Cap | 412.45M |
| Revenue (ttm) | 15.85M |
| Net Income (ttm) | -90.14M |
| Beta | 0.39 |
| EPS (ttm) | 1.43 |
| PE Ratio (ttm) | 2.91 |
| Forward PE | -5.51 |
| P/B (ttm) | 2.57 |
| P/S (ttm) | 26.03 |
| Earnings Date | Nov 5, 2026 |
| Ask | 5.55 |
| Volume | 397,839 |
| Avg. Volume (20D) | 750,170 |
| Open | 4.25 |
| Previous Close | 4.21 |
| Day's Range | 4.14 - 4.35 |
| 52-Week Range | 2.69 - 4.83 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About XFOR
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agre...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 16, 2017
Employees 45
Stock Exchange NasdaqCM
Ticker Symbol XFOR
Website https://www.x4pharma.com
Financial Performance
In 2025, X4 Pharmaceuticals's revenue was 35.11M, an increase of 1,273.21% compared to the previous year's 2.56M. Earnings were -79.2M, an increase of 111.48%.
Financial StatementsEarnings Surprise
X4 Pharmaceuticals has released their quarterly earnings on Aug 6, 2026:
X4 Pharmaceuticals Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2